{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:12:47Z","timestamp":1792714367914,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ebiom.2024.105074","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T20:58:33Z","timestamp":1710881913000},"page":"105074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-3614","authenticated-orcid":false,"given":"Sophie M.","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike M.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa E.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.J.","family":"Heijboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-3852","authenticated-orcid":false,"given":"Esther Oomen-de","family":"Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ebiom.2024.105074_bib1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105074_bib2","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"3","author":"Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105074_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10378","key":"10.1016\/j.ebiom.2024.105074_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ebiom.2024.105074_bib5","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ebiom.2024.105074_bib6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105074_bib7","article-title":"Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report","volume":"2","author":"Begum","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ebiom.2024.105074_bib8","article-title":"Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report","volume":"36","author":"Desai","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ebiom.2024.105074_bib9","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"9 Suppl","key":"10.1016\/j.ebiom.2024.105074_bib10","first-page":"S10","article-title":"OA03.06 - CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC [abstract]","volume":"17","author":"Li","year":"2022","journal-title":"World Conf Lung Cancer"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105074_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/ph14020119","article-title":"Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors","volume":"14","author":"van Eerden","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105074_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/ph14080796","article-title":"Cross-validation of a multiplex LC-MS\/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study","volume":"14","author":"Marin","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ebiom.2024.105074_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2022.07.015","article-title":"Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: an observational study","volume":"174","author":"Basak","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105074_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105074_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105074_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A\u00a0prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105074_bib22","article-title":"Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors","volume":"9","author":"Hurkmans","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105074_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1021\/acs.chemrestox.1c00307","article-title":"Relationships between the structure and severe drug-induced liver injury for low, medium, and high doses of drugs","volume":"35","author":"Ivanov","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105074_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"issue":"31","key":"10.1016\/j.ebiom.2024.105074_bib26","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.21.01371","article-title":"Dose optimization of sotorasib: is the US food and drug administration sending a message?","volume":"39","author":"Ratain","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.ebiom.2024.105074_bib27","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.21.02072","article-title":"Sotorasib: is maximum tolerated dose really the issue at hand?","volume":"39","author":"Souli\u00e8res","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105074_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105074_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jtho.2022.02.004","article-title":"Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001","volume":"17","author":"McCoach","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105074_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105074_bib31","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7781","key":"10.1016\/j.ebiom.2024.105074_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"Suppl_1","key":"10.1016\/j.ebiom.2024.105074_bib33","article-title":"LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"16","author":"J\u00e4nne","year":"2022","journal-title":"Ann Oncol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:05:34Z","timestamp":1738004734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S2352396424001099"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105074","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105074"}}